Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
45 / 100
Risk factors
The notice explicitly states this is not a public procurement under EU Directive, thus traditional procurement remedies...
No estimated value or volume commitments provided; actual business volume uncertain.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Sep 2027
- Supply of Aclidiniumbromid medicinal products under rebate contracts
- Contractual conditions are standard and non-negotiable
Show full summary
Open House procedure by Techniker Krankenkasse (TK) and two other German health insurers to conclude rebate contracts (Rabattverträge) under § 130a Abs. 8 SGB V for the active substance Aclidiniumbromid. The procedure is not a public procurement within the meaning of Directive 2014/24/EU but follows an open-house model where any eligible pharmaceutical company can join at any time during the contract period (max. 24 months from 01.10.2025 to 30.09.2027). No estimated value is disclosed. Only pharmaceutical companies with a valid marketing authorization for the relevant medicinal product and established in EU/EEA may participate. Award is based solely on eligibility, not on competitive evaluation.
Risks
The notice explicitly states this is not a public procurement under EU Directive, thus traditional procurement remedies...
No estimated value or volume commitments provided; actual business volume uncertain.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical company (pharmazeutischer Unternehmer) as defined in § 4 Abs. 18 AMG with respect to the offered product
- Company seat must be in Germany, another EU Member State, or EEA state
- Must hold a valid marketing authorization for the specific medicinal product or be otherwise entitled to market it
Requirements may be incomplete.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Originale Rabattverträge 2025-22 - Aclidiniumbromid
Rebate contracts for Aclidiniumbromid. All eligible pharmaceutical companies may conclude a contract on equal terms. No exclusivity. Continuous enrollment possible.
Location
Duration
Category
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Aclidiniumbromid zu schließen.
Show original TED data
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zum Wirkstoff Aclidiniumbromid zu schließen.
Procurement Details
- Publication date
- 18 Aug 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 541861-2025
Documents (1)
Similar tenders
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Belgium – Pharmaceutical products – Antimycotica
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Opportunity Score
Why this score?
Opportunity
55 / 100
Complexity
45 / 100
Risk factors
The notice explicitly states this is not a public procurement under EU Directive, thus traditional procurement remedies...
No estimated value or volume commitments provided; actual business volume uncertain.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications